問卷

TPIDB > Principal Investigator

Principal Investigator


Dalin Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation (在職)

Division of Dermatology

Division of Rheumatology

Hualien Tzu Chi Hospital (在職)

Division of Rheumatology

更新時間:2023-09-19

賴寧生
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

37Cases

2020-02-27 - 2024-01-31

Phase III

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    (1) Filgotinib; (2) Adalimumab

Participate Sites
13Sites

Terminated13Sites

2009-05-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-05-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-10-01 - 2012-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2011-01-31 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-04-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-01-01 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2023-05-31 - 2027-09-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-07-31 - 2026-04-30

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

1 2 3 4